secwatch.observer — SEC 8-K summary
======================================

Issuer:     LUMOS PHARMA, INC. (—)
CIK:        0001126234
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001193125-24-276512
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lumos Pharma acquired by DPV Parent for $4.25/share plus CVR; stock delisted
----------------------------------------------------------------------------

- Merger completed Dec 12, 2024; shareholders received $4.25 cash plus one non-transferable CVR per share.
- CVR entitles holders to milestone payments of up to $6.50 based on net revenue and company sale triggers.
- Tender offer closed with 75.62% of shares tendered; merger effected under DGCL Section 251(h).
- Total equity value of transaction approx $38 million; stock delisted from Nasdaq.
- Entire board resigned; Christopher Uzpen appointed sole director of surviving entity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/0001193125-24-276512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/d909721d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-276512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer